The fulvestrant dose response story
Introduction
Endocrine therapies provide effective and well-tolerated treatments for postmenopausal women with hormone receptor-positive breast cancer (estrogen receptor-positive [ER+] and/or progesterone receptor-positive [PgR+] ), both in the adjuvant setting 1 and for the treatment of advanced disease. 2 Aromatase inhibitors (AIs), which block production of estrogen through their interaction with the estrogen-producing enzyme aromatase, have demonstrated increased efficacy compared with the ER antagonist tamoxifen in postmenopausal women as first-line endocrine treatment for ER+ advanced breast cancer, [3] [4] [5] [6] and as adjuvant therapy for postmenopausal women with early breast cancer. [7] [8] [9] As such, AIs are now considered the standard of care as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive breast cancer.
Fulvestrant, a 17β-estradiol analog, is an ER antagonist that competes with endogenous estrogen for binding to the ER. 10 However, unlike tamoxifen, which exhibits partial estrogen agonist activity, fulvestrant has no recognized estrogenic effect. It is thought that this is due to the fact that upon binding to the ER, fulvestrant induces a conformational change, leading to degradation of the ER and complete inhibition of ER signaling in animal models. 11 Unfortunately, resistance to endocrine therapy will eventually develop. While optimal sequencing of appropriate hormone therapies is the ideal approach, very few randomized controlled trials have directly compared the effects of changing the order in which two different agents are given. 2 Furthermore, the paucity of data led the authors of a recent review to conclude that no definitive recommendations could be made regarding the sequencing of endocrine therapies in patients with advanced breast cancer, and that patients should receive the most efficacious treatment in that setting, whilst also considering specific side effect issues for that patient. 2 Early pre-clinical data demonstrated a lack of cross-reactivity between fulvestrant and tamoxifen with fulvestrant inhibiting growth of tamoxifen-resistant tumors. 12 Similarly in the clinical setting, many postmenopausal women with advanced breast cancer that responded to first-line fulvestrant remained responsive to further endocrine treatment. 13, 14 Furthermore, tumors that have responded to prior treatment with an antiestrogen 15, 16 or an AI 17, 18 may retain sensitivity to subsequent treatment with fulvestrant.
Pre-surgical studies provide the opportunity to perform a detailed analysis and comparison of biomarker expression and biomarker response to various experimental drug treatments. As an example, the selective estrogen receptor modulator tamoxifen was reported to increase PgR levels as a result of its partial estrogen agonist activity. 19 However, down regulation of ER with fulvestrant leads to reduction in PgR protein levels through disruption of ER-dependent transcription of the PgR gene, as shown in a randomized comparison with tamoxifen, highlighting the distinct mechanisms of action of these two agents. 20 Reduction in Ki67 expression, a nuclear antigen and marker of cell proliferation, is reported to correlate with treatment response to endocrine therapy in ER+ breast cancer, 21 and Ki67 in short-term neoadjuvant studies has been shown to predict outcome in long-term adjuvant trials. 22 Clinical efficacy of fulvestrant was demonstrated in postmenopausal women with advanced breast cancer that had progressed or recurred on prior antiestrogen therapy 16, 23, 24 and was originally approved at a monthly dose of 250 mg. However, a dose-dependent effect was subsequently shown, with improved progression-free survival (PFS) for fulvestrant 500 mg This review investigates the dose-dependent effects of fulvestrant more broadly, both in terms of the reduction of tumor biomarkers in the pre-surgical setting, and in clinical efficacy for the treatment of breast cancer.
Biological rationale for a dose-response relationship for fulvestrant
Dose-dependent reduction of tumor biomarkers following fulvestrant treatment was first demonstrated in a short-term pre-surgical study in postmenopausal women with primary breast cancer. 26 Following daily injections of a short-acting formulation of fulvestrant, reductions in ER expression and Ki67 labeling index were greater in patients with ER+ breast cancer who received a fulvestrant 18 mg daily injection compared with those who received a fulvestrant 6 mg daily injection.
We now extend the study of dose dependency by presenting a retrospective analysis of tumor biomarker data, extracted from three previously reported pre-surgical studies over a fulvestrant dose range of 50-500 mg, administered using the commercially available longacting formulation. Data from Study 18, 20 NEWEST (Neoadjuvant Endocrine Therapy for
Women with Estrogen-Sensitive Tumors), 27 and Trial 57 28 were combined in this analysis.
Study designs

Study 18
Study 18 was a randomized, multicenter, partially blinded study that compared placebo, tamoxifen, fulvestrant 50 mg, fulvestrant 125 mg, and fulvestrant 250 mg prior to surgery in postmenopausal women with previously untreated primary breast cancer. 20 Tumor biomarker expression data were analyzed by study using an analysis of covariance (ANCOVA) model (log-transformed ratio of post-to pre-treatment) with the log-transformed baseline value and treatment included as factors. The least squares mean and confidence interval (CI) values were back-transformed to the original scale. To assess the impact of fulvestrant dose while allowing for between-study variability, a second ANCOVA model was produced including log-transformed baseline, dose (as a continuous variable), and study as factors. The first ANCOVA included all treatment groups within each trial; the second ANCOVA included only placebo and the fulvestrant 50 mg, 125 mg, 250 mg, and 500 mg treatment groups. In order for the placebo data to be log-transformed, a dose of 0.5 mg rather than 0 mg was used for the purpose of this analysis.
ER H-score
In Study 18, NEWEST, and Trial 57, a dose-dependent effect was seen over the dose ranges investigated for reduction in ER expression. In each study, the greatest reduction in ER expression was seen with the highest fulvestrant dose. In Study 18, greater reduction in ER was observed for fulvestrant 250 mg versus tamoxifen, and in Trial 57, greater reduction in ER expression was observed for fulvestrant 500 mg versus anastrozole. In Trial 57, no additional reduction in ER expression was observed for fulvestrant 500 mg plus anastrozole compared with fulvestrant 500 mg alone (Table 1 ; Figure 1 ).
PgR H-score
A consistent dose-dependent effect of fulvestrant was also observed in Study 18, NEWEST, and Trial 57 for reduction in PgR expression. The greatest reduction in PgR expression was seen with the highest fulvestrant dose within each study. An increase in PgR expression was seen in the tamoxifen treatment group in Study 18. In Trial 57, no additional reduction in PgR expression was observed for the combination of fulvestrant 500 mg plus anastrozole compared with either fulvestrant 500 mg alone or anastrozole alone. Similar reductions in PgR expression were observed for fulvestrant 500 mg alone and anastrozole alone ( Table 2 ; Figure 2 ).
Ki67 labeling index
Ki67 labeling index was reduced following treatment in each fulvestrant treatment group in each study. In Study 18 and NEWEST, the greatest reduction in Ki67 labeling index was seen with the highest fulvestrant dose. In Trial 57, which also included the small initial cohort of patients treated with fulvestrant 250 mg (n=6), there were no meaningful differences in Ki67 labeling index reduction between the fulvestrant treatment groups (Table 3 ; Figure 3 ).
Overall results from the ANCOVA model show a consistent dose-dependent effect for fulvestrant over the dose ranges analyzed for ER and PgR H-score and Ki67 labeling index.
Results for the second ANCOVA, which adjusted for between-study variability, show that increasing fulvestrant dose results in greater reduction in ER and PgR H-score and Ki67 labeling index (p<0.0001 for the dose-response relationship for each biomarker).
Clinical evidence of a dose-response relationship for fulvestrant
Fulvestrant dose-response in second-line therapy for advanced breast cancer
The clinical efficacy of fulvestrant at a dose of 250 mg/month was established in the registration trials 0020 and 0021, which compared fulvestrant 250 mg with anastrozole for the treatment of postmenopausal women with advanced breast cancer that had progressed or recurred on prior antiestrogen therapy. 23, 24 In a combined analysis of data from both studies (fulvestrant, n=428; anastrozole, n=423), fulvestrant 250 mg was shown to be at least as (Table 4) . 25 Importantly, the dose-dependent clinical efficacy seen in CONFIRM was not associated with a dose-dependent increase in toxicity, with no substantial differences between the treatment groups in terms of incidence and severity of adverse events. This increase in therapeutic index led to fulvestrant 500 mg becoming the therapy for advanced disease. 30 As anastrozole was previously shown to demonstrate improvements in efficacy over tamoxifen, 3 this was considered a surprising outcome for fulvestrant 250 mg. However, with the almost immediate separation of the TTP curves in this trial, it was hypothesized that the 3-6 months to steady state for the fulvestrant 250 mg regimen could have led to the under-performance of this treatment group.
In the Phase II FIRST study (Fulvestrant fIRst-line Study comparing endocrine Treatments), fulvestrant 500 mg was compared with anastrozole in postmenopausal women with advanced breast cancer who had not received endocrine therapy for advanced disease. The fulvestrant 500 mg dose regimen, which includes a 500 mg dose at Day 14, was shown to be at least as effective as anastrozole in terms of the primary endpoint of clinical benefit rate (fulvestrant, 72.5%; anastrozole, 67.0%) and the secondary endpoint of TTP was significantly longer for fulvestrant 500 mg compared with anastrozole. 31 Safety data indicated that fulvestrant 500 mg has a similar tolerability profile compared with anastrozole 1mg, and is well tolerated as 
Fulvestrant in combination therapy
Together with its distinct mechanism of action and reduced risk of cross-resistance with other endocrine treatments, the observation of incomplete ER reduction with fulvestrant 250 mg, both in the short, 20 medium, and long term 32, 33 . 34 The overall incidence of AEs was similar between the two treatment groups.
Secondary endpoints including objective response rate, clinical benefit rate and overall survival were also similar between the two study arms, indicating no benefit for the anastrozole plus fulvestrant combination over anastrozole alone.
The randomized Phase III SWOG S0226 trial also compared the combination of anastrozole plus fulvestrant 250 mg + LD with anastrozole alone as first-line therapy for postmenopausal women with metastatic breast cancer. 35 The primary endpoint of PFS was significant in favor of the combination group: 15.0 months compared with 13. p=0.37). 35 In total, 166 out of 514 patients (32.3%) had received no prior adjuvant endocrine therapy in the FACT trial, whereas 414 out of 694 patients (59.7%) were naïve to prior tamoxifen in SWOG S0226. In both trials, less than 2% of patients had received adjuvant therapy with an AI. As the percentage of patients who were naïve to prior adjuvant endocrine treatment was lower in the FACT trial, and any potential differences in clinical effectiveness may be more pronounced when comparing endocrine agents in hormone-naïve patients, this Other than the SWOG S0226 trial, clinical data do not support the combination of an antiestrogen with an AI. While it is possible that the fulvestrant 250 mg loading dose used in the FACT and SoFEA trials was sub-optimal and that efficacy might have been improved with the 500 mg dose, biological data using fulvestrant 500 mg do not suggest there will be an additional benefit by adding an AI to fulvestrant 500 mg. 28 Unfortunately, the SWOG S0226 trial did not have a third treatment arm of fulvestrant 250 mg alone, which would have clarified whether the longer TTP seen with the combination would have been achieved with fulvestrant alone in the first-line setting. The data from SWOG S0226 should therefore be used to generate hypotheses for studies to understand if and why this finding is real.
The dose-dependent effect on tumor biomarkers seen here in postmenopausal women may also be evident in pre-menopausal women receiving fulvestrant in clinical studies. In contrast to postmenopausal women, where fulvestrant 250 mg was shown to be effective in reducing ER, PgR, and Ki67, a previous study demonstrated that fulvestrant 250 mg did not effectively reduce expression of ER, PgR, or Ki67 in pre-menopausal women, who are known to have much higher levels of circulating estrogen which would be expected to compete with fulvestrant for binding to ER. 37 A single fulvestrant dose of 750 mg was subsequently shown to reduce ER levels in pre-menopausal women with primary breast cancer, to an extent similar to that seen with fulvestrant 250 mg in postmenopausal women, suggesting a doseresponse relationship for fulvestrant in these patients. 38 The dose-dependent biomarker data presented here also correspond to the previously-reported pharmacokinetic profile of fulvestrant. Following a single injection of either fulvestrant 50 mg, 125 mg, or 250 mg, dose-linear pharmacokinetics were observed. 39 In the NEWEST study, plasma levels and exposure with fulvestrant 500 mg were approximately double that of fulvestrant 250 mg at Week 16, demonstrating a linear dose-dependent effect. 40 In addition to increasing the monthly fulvestrant dose in postmenopausal women, early pharmacokinetic and clinical data suggested that alternative regimens could be utilized to increase clinical efficacy. At the fulvestrant 250 mg/month dose, it takes 3-6 months to achieve steady-state plasma levels. 41 27, 28 raises the possibility that greater reductions in ER expression and improved efficacy could be achieved using an even higher fulvestrant dose. Fulvestrant 750 mg, although requiring three separate 5 ml intramuscular injections, has previously been shown to be well tolerated, and is effective in reducing ER expression in pre-menopausal women. 38 However to our knowledge, no studies using a dose higher than fulvestrant 500 mg for postmenopausal breast cancer have been reported, and three or more 5 mL injections per (Table 4) . Although efficacy and safety were established for each of the fulvestrant doses in both studies, the relatively small sample sizes did not allow for any potential differences in efficacy to be determined between the treatment groups. 43, 44 Importantly, the biological and clinical studies analyzed here were not conducted concurrently, and indirect cross-trial comparisons should be interpreted with caution.
Significant variability was observed between these studies both for absolute levels, and magnitude of treatment-driven change, of ER and PgR H-score and Ki67 labeling index.
Factors that may have influenced this between-study variability include the different antibodies and antibody retrieval methods that were used in each of the studies, and the assay sensitivity, which was lower in the earlier Study 18 than NEWEST and Trial 57, where assay sensitivity was very high in order to reduce false-negative results. 27 In addition, the time from dose to surgery or biopsy varied between the studies. However, when adjusting for betweenstudy variability in the analysis of tumor biomarker reduction using the second ANCOVA, fulvestrant demonstrated a strong dose-response relationship for reduction in ER, PgR, and Ki67 index.
Conclusion
Overall, the dose-response effect seen with fulvestrant in clinical studies in the advanced disease setting mirrors the dose-dependent reduction in tumor biomarker studies in a much earlier disease setting. Across all of the datasets analyzed here, a dose-response relationship has been demonstrated. This represents a strong demonstration of the relationship between the biology of tumor biomarkers and clinical efficacy which underpins rational drug development. 
